Stockscreener 앱 받기
7.94
3.87%
-0.32
전일 마감가:
$8.26
열려 있는:
$8.29
하루 거래량:
64,834
Relative Volume:
0.81
시가총액:
$48.86M
수익:
$7.97M
순이익/손실:
$-75.74M
주가수익비율:
-0.3269
EPS:
-24.2853
순현금흐름:
$-85.33M
1주 성능:
-11.78%
1개월 성능:
-30.78%
6개월 성능:
-8.53%
1년 성능:
-74.88%
1일 변동 폭
$7.94
$8.6437
1주일 범위
$7.94
$9.43
52주 변동 폭
$3.76
$34.37
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.94 | 50.83M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-18 | 재개 | H.C. Wainwright | Buy |
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
(ALGS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market - TipRanks
Aligos therapeutics appoints James Hassard as chief commercial officer By Investing.com - Investing.com Nigeria
Geopolitics Watch: Why retail investors favor Aligos Therapeutics Inc stockPrice Action & Risk Controlled Daily Plans - Bộ Nội Vụ
Why retail investors favor Aligos Therapeutics Inc. stockInflation Watch & Verified Swing Trading Watchlist - Bộ Nội Vụ
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Investing News Network
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos therapeutics appoints James Hassard as chief commercial officer - Investing.com India
Aligos Therapeutics strengthens senior leadership team with the appointment of James Hassard as executive vice president, chief commercial officer - marketscreener.com
Aligos Therapeutics Presents Positive Data at HEP-DART 2025 - Investing News Network
Why Aligos Therapeutics Inc. stock could be next big winnerJuly 2025 Recap & Accurate Entry and Exit Point Alerts - Улправда
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades Aligos Therapeutics (NASDAQ:ALGS) to "Strong-Buy" - MarketBeat
Why analysts upgrade Aligos Therapeutics Inc. stock2025 Market Trends & Community Consensus Trade Signals - Улправда
How resilient is Aligos Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Why analysts remain bullish on Aligos Therapeutics Inc. stockJuly 2025 Movers & Daily Volume Surge Trade Alerts - Улправда
Trend Recap: Does Aligos Therapeutics Inc. stock trade at a discount to peers2025 Price Action Summary & Daily Stock Trend Watchlist - ulpravda.ru
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics - The Manila Times
UBS Initiates Coverage of Aligos Therapeutics (ALGS) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on ALGS with a Buy Rating and $20 PT | AL - GuruFocus
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline - Investing.com
(ALGS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Is Aligos Therapeutics Inc a good long term investmentValue Traps to Avoid & Diversify Intelligently to Avoid Big Hits - earlytimes.in
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics Inc 5WK0 Stock Analysis and ForecastEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in
Aug PreEarnings: How Aligos Therapeutics Inc 5WK0 stock reacts to fiscal policies2025 Pullback Review & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% – Time to Sell? - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5%Time to Sell? - MarketBeat
Aligos Therapeutics secures $105 million in private placement - MSN
Technical Reactions to ALGS Trends in Macro Strategies - Stock Traders Daily
Can Aligos Therapeutics Stock Recover If Markets Fall? - Trefis
Analyst Calls: Why Aligos Therapeutics Inc. stock is rated strong buyJuly 2025 Decliners & Community Consensus Trade Signals - DonanımHaber
Why Aligos Therapeutics Inc. stock is a must watch in 20252025 Trade Ideas & Free Fast Gain Swing Trade Alerts - DonanımHaber
Aligos Therapeutics Earnings Notes - Trefis
Gainers Report: Does Aligos Therapeutics Inc stock trade at a discount to peers2025 Technical Overview & Expert Approved Momentum Ideas - moha.gov.vn
Hepatitis B Virus Infection Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
What analysts say about Aligos Therapeutics Inc stockPrice-to-Earnings Ratio Insights & Minimal Investment Portfolio - earlytimes.in
Aligos Therapeutics, Inc. (ALGS) Fundamental Analysis - Meyka
Aligos Therapeutics (ALGS) Issues Stock Options to New Employees - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Aligos reports synergistic weight loss effect with THR-β agonist By Investing.com - Investing.com South Africa
Aligos reports synergistic weight loss effect with THR-β agonist - Investing.com
Aligos Therapeutics (ALGS) Unveils Promising Data at HEP-DART 20 - GuruFocus
Aligos Therapeutics Highlights Positive Data on Pevifoscorvir Sodium and ALG-055009 at HEP-DART 2025 Meeting - Quiver Quantitative
Aligos Therapeutics, Inc. Presents Positive Data at HEP-DART 2025 - marketscreener.com
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely - Sahm
Contrasting Neurogene (NASDAQ:NGNE) & Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
Why Aligos Therapeutics Inc. (5WK0) stock could be next leaderWeekly Trend Summary & Safe Capital Growth Plans - Newser
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):